BPA for ravicti, buphenyl, krystexxa, procysbi, uplizna
Ended Awarded Last action
- Contract number
- 36E79724A0031
- Awardee
-
Horizon Therapeutics Usa, Inc. UEI SK1UK7S74GB3
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $31,375,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Horizon Therapeutics USA Inc. has been awarded a single-award Blanket Purchase Agreement (BPA) valued at $31.375 million by the Department of Veterans Affairs (VA) National Acquisition Center, effective from September 20, 2024, through October 29, 2025. This BPA, established under the GSA Schedule for Pharmaceuticals and Drugs (FSS-61-IB) with no set-aside designation, authorizes the VA and its Veterans Integrated Service Networks (VISNs) to place firm fixed-price delivery orders for specialty pharmaceutical products. The contract encompasses five key medications: Ravicti, Buphenyl, Krystexxa, Procysbi, and Uplizna—all specialty drugs developed and commercialized by Horizon Therapeutics for the treatment of rare, autoimmune, and severe inflammatory diseases.
The BPA structure enables VA medical centers and VISNs across the United States to efficiently procure these critical specialty pharmaceuticals through individual task orders without requiring separate competitive solicitations for each purchase. Krystexxa (pegloticase), an 8mg pharmaceutical indicated for chronic gout management, represents a significant portion of Horizon's historical delivery volume to the VA healthcare system. This IDV complements Horizon's existing $25 million GSA Schedule contract and positions the company as a primary supplier of orphan drugs and targeted treatments to the VA, supporting the agency's mission to deliver specialized medical therapies to the veteran population. The BPA's firm fixed-price structure provides budget certainty for the VA while streamlining procurement processes for these medically necessary specialty pharmaceuticals.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724A0031?
36E79724A0031 was awarded to Horizon Therapeutics Usa, Inc. by National Acquisition Center (Headquarters) on September 20, 2024.
How much is contract 36E79724A0031 worth?
36E79724A0031's own ceiling is $31,375,000.
Who can order from contract 36E79724A0031?
36E79724A0031 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79724A0031 under another contract?
Yes. 36E79724A0031 is a blanket purchase agreement under 36F79719D0224, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79724A0031 competed?
The extent of competition for 36E79724A0031 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV